Repeated enquiries and complaints by Baggerly and Coombes led senior officials at the University of Texas to advise them to drop what was starting to look like a vendetta. “We were focused on the fact that the data used to justify clinical trials were wrong; we thought that should be enough,” says Baggerly. “How the data got in this shape was not our immediate concern.”